Trimebutine-d5 (fumarate)

• UNSPSC Description:

  Trimebutine-d5 (fumarate) is deuterium labeled Trimebutine.

• Target Antigen:

  Isotope-Labeled Compounds; Opioid Receptor

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling;Others

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease

• Solubility:

  10 mM in DMSO

• Smiles:

  OC(/C=C/C(O)=O)=O.O=C(C1=CC(OC)=C(C(OC)=C1)OC)OCC(C([2H])([2H])C([2H])([2H])[2H])(C2=CC=CC=C2)N(C)C

• Molecular Weight:

  508.57

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Hiyama, T., et al., Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract. J Gastroenterol Hepatol, 2009. 24(4): p. 537-46.|[3]Kaneto, H., M. Takahashi, and J. Watanabe, The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies. J Pharmacobiodyn, 1990. 13(7): p. 448-53.|[4]Roman, F.J., et al., Pharmacological properties of trimebutine and N-monodesmethyltrimebutine. J Pharmacol Exp Ther, 1999. 289(3): p. 1391-7.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2747915-18-8